

# **C**LINICAL **P**HARMACOLOGY *and* **T**HERAPEUTICS

## **Editor**

Walter Modell, M.D.

## **Associate Editor**

Marcus M. Reidenberg, M.D.

## **Editorial Board**

Alvito P. Alvares, Ph.D.

Arthur J. Atkinson, Jr., M.D.

Daniel L. Azarnoff, M.D.

Frank M. Berger, M.D., D.Sc.

Karl H. Beyer, Jr., M.D., Ph.D.

Thorir D. Bjornsson, M.D.

Terrence F. Blaschke, M.D.

Paul Calabresi, M.D.

Donald B. Calne, M.D.

Edward A. Carr, Jr., M.D.

Allan H. Conney, Ph.D.

T. S. Danowski, M.D.

Arthur C. DeGraff, M.D.

Peter Dineen, M.D.

Edward F. Domino, M.D.

Alvan R. Feinstein, M.D.

Vladimir Fencel, M.D.

Robert B. Forney, Ph.D.

Emil Frei III, M.D.

Milo Gibaldi, Ph.D.

Leo E. Hollister, M.D.

Leonard Horowitz, Ph.D.

Aryeh Hurwitz, M.D.

Murray E. Jarvik, M.D.

Werner Kalow, M.D.

Stanley A. Kaplan, Ph.D.

Arthur S. Keats, M.D.

Henn Kutt, M.D.

Louis Lasagna, M.D.

Paul S. Leitman, M.D., Ph.D.

Louis Lemberger, M.D., Ph.D.

Gerhard Levy, Pharm.D.

T. A. Loomis, M.D., Ph.D.

David T. Lowenthal, M.D.

Daniel S. Lukas, M.D.

Arno G. Motulsky, M.D.

Alan S. Nies, M.D.

Lawrence G. Raisz, M.D.

Albert Sjoerdsma, M.D., Ph.D.

Jay Tepperman, M.D.

Leroy D. Vandam, M.D.

Elliot S. Vesell, M.D.

John G. Wagner, Ph.D.

E. Leong Way, Ph.D.

Richard Weinshilboum, M.D.

Louis Weinstein, M.D.

Alastair J. J. Wood, M.B., Ch.B.

**Volume 35, January-June, 1984**

**The C. V. Mosby Company, St. Louis**

Volume 35  
Copyright © 1984 by  
The C. V. Mosby Company

*All rights reserved*

*Printed in the United States of America*

## Index to volume 35

### Author index

#### A

- Abernethy DR, Greenblatt DJ, Eshelman FN, Shader RI: Ranitidine does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam, 188  
—, —, Shader RI: Imipramine disposition in users of oral contraceptive steroids, 792  
—, —, —: Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection, 348  
—: *see* Martyn et al, 535  
Abi-Samra F: *see* Fouad et al, 768  
Agrawal N: *see* Ryan et al, 90  
Akdamar K: *see* McMahon et al, 852  
—: *see* Ryan et al, 90  
Alexander N: *see* Vlachakis et al, 782  
Alexopoulos GS: *see* Young et al, 540  
Allen M: *see* Moore et al, 40  
—: *see* Moore et al, 641  
Anderson KE: *see* Pantuck et al, 161  
Aogaichi K: *see* Brazzell et al, 307  
Arakawa M: *see* Yoshida et al, 681  
Arendshorst W: *see* Cubeddu et al, 576  
Arnold JD, Mullane JF, Hayden DM, March L, Hart K, Perdomo CA, Fencik M, Berger AE: Etodolac, aspirin, and gastrointestinal microbleeding, 716  
Assael BM: *see* Palminteri et al, 141  
Atkinson AJ, Becker RE, Galletti PM, Jefferis JE, Wroblewski R: University and pharmaceutical industry cooperation: the need to plan for the future, 431  
—: *see* Frederiksen et al, 387  
Attwood J: *see* Miners et al, 480

#### B

- Bakke OM, Wardell WM, Lasagna L: Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: issues of safety, 559

- Baldwin D: *see* Moore et al, 40  
—: *see* Moore et al, 641  
Barde SH: *see* Svensson et al, 660  
Barr CE: *see* Das et al, 317  
Barr J: *see* Vlachakis et al, 782  
Bauer LA, Davis R, Wilensky A, Raisys V, Levy RH: Diurnal variation in valproic acid clearance, 505  
Beaver WT: *see* Forbes et al, 843  
Beck B: *see* Reddy et al, 610  
Becker RE: *see* Atkinson et al, 431  
Benes J: *see* Reddy et al, 610  
Benowitz NL, Jacob P III: Daily intake of nicotine during cigarette smoking, 499  
—: *see* Hall et al, 810  
Bentivoglio M: *see* Corea et al, 776  
Berger AE: *see* Arnold et al, 716  
Bernhard H: *see* Smith et al, 487  
Bertilsson L: *see* Dahlqvist et al, 815  
Bianchetti G: *see* Palminteri et al, 141  
Biggs DF: *see* Edelman et al, 382  
Birkett DJ: *see* Dahlqvist et al, 815  
—: *see* Miners et al, 408  
—: *see* Wing et al, 695  
Bjornsson TD: *see* Ellinwood et al, 360  
Blair AD, Maxwell BM, Forland SC, Jacob L, Cutler RE: Cefonicid kinetics in subjects with normal and impaired renal function, 798  
Bobik A: *see* Jennings et al, 594  
Bochner F: *see* Günsberg et al, 585  
Boer WH: *see* Reeves et al, 461  
Borner K: *see* Kampf et al, 214  
Bowshe DJ: *see* Frederiksen et al, 387  
Branch RA: *see* Küpfer et al, 33  
Bravo EL: *see* Fouad et al, 768  
Brazzell RK, Aogaichi K, Heger JJ Jr, Somberg JC, Carliner NH, Morganroth J: Cibenzoline plasma concentration and antiarrhythmic effect, 307  
Breen KJ: *see* Desmond et al, 338  
Breimer DD: *see* DeLeede et al, 148  
Brooks BA: *see* McNabb et al, 328  
Brown KF: *see* Walker et al, 686

- Bubrick MP: *see* Pancorbo et al, 50  
 Buchanan WW: *see* Kean et al, 627  
 Bullingham R: *see* Moore et al, 40  
 —: *see* Moore et al, 641  
 Burns RS, Gopinathan G, Hümpel M, Dorow R,  
 Calne DB: Disposition of oral lisuride in  
 Parkinson's disease, 548  
 Byyny RL: *see* Hiatt et al, 12

## C

- Calne DB: *see* Burns et al, 548  
 Calvarese B: *see* Gong et al, 26  
 Campbell NRC, Dunnette JH, Mwaluko G, Van Loon  
 J, Weinshilboum RM: Platelet phenol sul-  
 fotransferase and erythrocyte catechol-O-  
 methyltransferase activities: correlation  
 with methyl dopa metabolism, 55  
 Carliner NH: *see* Brazzell et al, 307  
 Carlson J: *see* Das et al, 317  
 Carr EA Jr: Scintigraphy and nuclear magnetic re-  
 sonance: their potential applications in phar-  
 macology; New radiopharmaceuticals and  
 spin drugs: their potential implications for  
 scintigraphy and nuclear magnetic reso-  
 nance. I, 94; II, 131  
 Chachich BM: *see* Forbes et al, 843  
 Cham B: *see* Günsberg et al, 585  
 Chapman KR, Smith DL, Rebuck AS, Leenen FHH:  
 Hemodynamic effects of an inhaled beta-2  
 agonist, 762  
 Chasseaud LF: *see* Major et al, 653  
 Chatterji D: *see* Zimm et al, 826  
 Chiang ST: *see* Morrison et al, 646  
 Chin TWF: *see* Pancorbo et al, 50  
 Chung M, Hilbert JM, Gural RP, Radwanski E, Sym-  
 chowicz S, Zampaglione N: Multiple-dose  
 halazepam kinetics, 838  
 —, —, —, —, —: Multiple-dose quazepam  
 kinetics, 520  
 Christian CD Jr: *see* Meredith et al, 474  
 Cicalese C: *see* Linday et al, 438  
 Claris-Appiani A: *see* Palminteri et al, 141  
 Cloutier G: *see* Cubeddu et al, 576  
 Cole A: *see* Moore et al, 40  
 Collins JM: *see* Zimm et al, 826  
 Conney AH: *see* Pantuck et al, 161  
 Cook CE: *see* Kramer et al, 416  
 Corea L, Bentivoglio M, Verdecchia P, Motolese  
 M, Sorbini CA, Grassi V, Tantucci C:  
 Noninvasive assessment of chronotropic  
 and inotropic response to preferential  
 beta-1 and beta-2 adrenoceptor stimulation,  
 776  
 Cosgriff J: *see* Miller et al, 666  
 Cowart D: *see* Olanoff et al, 755  
 Coyle D: *see* Denson et al, 409  
 —: *see* Denson et al, 702

- Cubeddu LX, Cloutier G, Gross K, Grippo R, Tanner  
 L, Lereia L, Shakarjian M, Knowlton G,  
 Harden TK, Arendshorst W, Rogers JF:  
 Bupropion does not antagonize cardiovas-  
 cular actions of clonidine in normal subjects  
 and spontaneously hypertensive rats, 576  
 Cumbo TJ: *see* Reitberg et al, 64  
 Cunningham E: *see* Nascimento et al, 342  
 Cutler RE: *see* Blair et al, 798

## D

- Dahlqvist R, Bertilsson L, Birkett DJ, Eichelbaum  
 M, Säwe H, Sjöqvist F: Theophylline me-  
 tabolism in relation to antipyrine, debriso-  
 quine, and sparteine metabolism, 815  
 Darragh A: *see* Major et al, 653  
 Das G, Barr CE, Carlson J: Reduction of digoxin  
 effect during digoxin-quinidine interaction,  
 317  
 Davis R: *see* Bauer et al, 505  
 Dawe MA: *see* Gault et al, 74  
 —: *see* Gault et al, 750  
 de Boer AG: *see* de Leede et al, 148  
 de Lange S: *see* de Leede et al, 148  
 de Leede LGJ, Hug CC Jr, de Lange S, de Boer AG,  
 Breimer DD: Rectal and intravenous pro-  
 pranolol infusion to steady state: Kinetics  
 and  $\beta$ -receptor blockade, 148  
 DeLeve L: *see* Reeves et al, 461  
 Dennis S: *see* Wills et al, 722  
 Denson D, Coyle D, Thompson G, Myers J: Alpha-  
 acid glycoprotein and albumin in human  
 serum bupivacaine binding, 409  
 —, —, —, Santos D, Turner PA, Myers JA, Knapp  
 R: Bupivacaine protein binding in term par-  
 turient: effects of lactic acidosis, 702  
 Desmond PV, Mashford ML, Harman PJ, Morphet  
 BJ, Breen KJ, Wang YM: Decreased oral  
 warfarin clearance after ranitidine and ci-  
 metidine, 338  
 —: *see* Küpfer et al, 33  
 de Wolff FA: *see* Edelbroek et al, 467  
 Dhar AK: *see* Young et al, 540  
 Diqet B: *see* Thiercelin et al, 510  
 Dorow R: *see* Burns et al, 548  
 Drayer DE: *see* Linday et al, 438  
 Dunnette JH: *see* Campbell et al, 55  
 Durkin J: *see* Luderer et al, 19

## E

- Easler EE: *see* Ellinwood et al, 360  
 Ebert RV, McNabb ME, Snow SL: Effect of nicotine  
 chewing gum on plasma nicotine levels of  
 cigarette smokers, 495  
 Ebert MH: *see* Martin et al, 322  
 Edefonti A: *see* Palminteri et al, 141

- Edelbroek PM, Zitman FG, Schreuder JN, Rooymans HGM, de Wolff FA: Amitriptyline metabolism in relation to antidepressive effect, 467  
Edelman J, Biggs DF, Jamali F, Russell AS: Low-dose methotrexate kinetics in arthritis, 382  
Edsbäcker S: *see* Ryrfeldt et al, 525  
Eichelbaum M: *see* Dahlqvist et al, 815  
Ellingboe J: *see* Mendelson et al, 545  
Ellinwood EH Jr, Easler EE, Linnoila M, Molter DW, Heatherly DG, Björnsson TD: Effects of oral contraceptives on diazepam-induced psychomotor impairment, 360  
Elliott HL, Vincent J, Hughes DMA, Meredith PA, Reid JL: Trimazosin in normotensive subjects, 156  
Ensminger WD: *see* Gyves et al, 83  
Ertan A: *see* McMahon et al, 852  
—: *see* Ryan et al, 90  
Eshelman FN: *see* Abernethy et al, 188  
—: *see* Holloway et al, 203  
—: *see* Smith et al, 487

# F

- Fencik M: *see* Arnold et al, 716  
Fine A: *see* Gault et al, 74  
—: *see* Gault et al, 750  
FitzGerald GA, Oates JA: Selective and nonselective inhibition of thromboxane formation, 633  
Foенander T: *see* Wing et al, 695  
Forbes JA, Kolodny AL, Chachich BM, Beaver WT: Nalbuphine, acetaminophen, and their combination in postoperative pain, 843  
Forland SC: *see* Blair et al, 798  
Fouad FM, Pedrinelli R, Bravo EL, Abi-Samra F, Textor SC, Tarazi RC: Clinical and systemic hemodynamic effects of nitrendipine, 768  
Fradl DC: *see* Hiatt et al, 12  
Frederiksen MC, Bowsher DJ, Ruo TI, Henthorn TK, Ts'ao C-H, Green D, Atkinson AJ Jr: Kinetics of epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects in normal subjects, 387  
Freilich DI, Giardina E-GV: Imipramine binding to alpha-1-acid glycoprotein in normal subjects and cardiac patients, 670  
Fujita M: *see* Yoshida et al, 681  
Fukuda R: *see* Yoshida et al, 681  
Fuseau E, Sheiner LB: Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model, 733

# G

- Gaffney TE: *see* Olanoff et al, 755  
Galletti PM: *see* Atkinson et al, 431  
Gault MH, Longerich L, Dawe M, Fine A: Digoxin-rifampin interaction, 750

- , —, Loo JCK, Ko PTH, Fine A, Vasdev SC, Dawe MA: Digoxin biotransformation, 74  
Ghesquière F: *see* Thiercelin et al, 510  
Giardina E-GV: *see* Freilich and Giardina, 670  
Gibson DM: *see* Wills et al, 722  
Gilbertson S: *see* Gyves et al, 83  
Giles TD, Sander GE, Kaneish A, Quiroz AC: Time-dependent antihypertensive effect of carteolol—beta-adrenoceptor antagonist with partial agonist activity, 301  
Goldberg MJ: *see* Radomski et al, 402  
Goldstein A: *see* Mendelson et al, 545  
Gomeni R: *see* Palminteri et al, 141  
Gong H Jr, Tashkin DP, Simmons MS, Calvarese B, Shapiro BJ: Acute and subacute bronchial effects of oral cannabinoids, 26  
Good F: *see* Rajchgot et al, 394  
Gopinathan G: *see* Burns et al, 548  
Gordon EK: *see* Martin et al, 322  
Graham G: *see* Günsberg et al, 585  
Grassi V: *see* Corea et al, 776  
Green D: *see* Frederiksen et al, 387  
Greenblatt DJ: *see* Abernethy et al, 188  
—: *see* Abernethy et al, 348  
—: *see* Abernethy et al, 792  
—: *see* Martyn et al, 535  
Grippe R: *see* Cubeddu et al, 576  
Gross K: *see* Cubeddu et al, 576  
Günsberg M, Bochner F, Graham G, Imhoff D, Parsons G: Disposition of clinical response to salicylates in patients with rheumatoid disease, 585  
Gural RP: *see* Chung et al, 520  
—: *see* Chung et al, 838  
Gyves JW, Ensminger WD, Stetson P, Niederhuber JE, Meyer M, Walker S, Janis MA, Gilbertson S: Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system, 83

# H

- Hall SM, Herning RI, Jones RT, Benowitz NL, Jacob P III: Blood cotinine levels as indicators of smoking treatment outcome, 810  
Halperin J: *see* Reder et al, 454  
Harden TK: *see* Cubeddu et al, 576  
Harding E: *see* Rajchgot et al, 394  
Harman PJ: *see* Desmond et al, 338  
Hart K: *see* Arnold et al, 716  
Hayden DM: *see* Arnold et al, 716  
Heatherly DG: *see* Ellinwood et al, 360  
Hedner T, Nyberg G, Mellstrand T: Guanfacine in essential hypertension: effects during rest and isometric exercise, 604  
Heger JJ Jr: *see* Brazzell et al, 307  
Henauer SA, Hollister LE: Cimetidine interaction with imipramine and nortriptyline, 183  
Henthorn TK: *see* Frederiksen et al, 387  
Herning RI: *see* Hall et al, 810

- Hiatt WR, Fradl DC, Zerbe GO, Byyny RL, Nies AS: Selective and nonselective  $\beta$ -blockade of peripheral circulation, 12
- Hilbert JM: *see* Chung et al, 520
- : *see* Chung et al, 838
- Holley FO, Ponganis KV, Stanski DR: Effects of cardiac surgery with cardiopulmonary bypass on lidocaine disposition, 617
- Hollister LE: *see* Henauer and Hollister, 183
- Holloway RH, Kuljian B, Eshelman F, McCallum RW: Effects of ranitidine and of cimetidine on pentagastrin-stimulated gastric acid secretion, 203
- Holtzman JL: *see* Kramer et al, 416
- Hoppe-Seyler G: *see* Keller et al, 208
- Hopper M: *see* Kantor and Hopper, 46
- Howell SB: *see* Shea et al, 419
- Hug CC Jr: *see* de Leede et al, 148
- Hughes DMA: *see* Elliott et al, 156
- Hümpel M: *see* Burns et al, 548
- Hunniset A: *see* Moore et al, 641

## I

- Imhoff D: *see* Günsberg et al, 585
- Inaba T: *see* Jurima et al, 426
- Ito K: *see* Yoshida et al, 681

## J

- Jacob L: *see* Blair et al, 798
- Jacob P III: *see* Benowitz and Jacob, 499
- : *see* Hall et al, 810
- Jamali F: *see* Edelman et al, 382
- Janis MA: *see* Gyves et al, 83
- Jansen A: *see* Keller et al, 208
- Jefferis JE: *see* Atkinson et al, 431
- Jennings G, Bobik A, Oddie C, Restall R: Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol, 594
- Johnson GF: *see* Radomski et al, 402
- Johnson RF: *see* Meredith et al, 474
- Jones RT: *see* Hall et al, 810
- Judson BA: *see* Mendelson et al, 545
- Jurima M, Inaba T, Kalow W: Sparteine oxidation by the human liver: absence of inhibition by mephenytoin, 426

## K

- Kalow W: *see* Jurima et al, 426
- Kampf D, Borner K, Möller M, Kessel M: Kinetic interactions between axlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function, 214
- Kaneish A: *see* Giles et al, 301
- Kantor TG, Hopper M: Oral nalbuphine in postpartum pain, 46
- Kappas A: *see* Pantuck et al, 161
- Kean WF, Kassam YB, Lock CJL, Buchanan WW, Rischke J, Nablo L: Antithrombin activity of gold sodium thiomalate, 627

- Keats AS: *see* Romagnoli and Keats, 367
- Keller E, Jansen A, Pelz K, Hoppe-Seyler G, Schollmeyer P: Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis, 208
- Kessel M: *see* Kampf et al, 214
- Khan MAA: *see* Linday et al, 438
- Klein J: *see* Rajchgot et al, 394
- Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD: Nifedipine: kinetics and dynamics in healthy subjects, 742
- Ko PTH: *see* Gault et al, 74
- Koepke HH: *see* Morrison et al, 646
- Kolodny AL: *see* Forbes et al, 843
- Kopin IJ: *see* Martin et al, 322
- Kozioł JA: *see* Shea et al, 419
- Knapp R: *see* Denson et al, 702
- Knowlton G: *see* Cubeddu et al, 576
- Kramer P, Tsuru M, Cook CE, McClain CJ, Holtzman JL: Effect of influenza vaccine on warfarin anticoagulation, 416
- Kuljian B: *see* Holloway et al, 203
- Kunka RL, Venkataramanan R, Stern RM, Ladik CF: Excretion of propoxyphene and norpropoxyphene in breast milk, 675
- Kupersmith J: *see* Reder et al, 454
- Küpfer A, Desmond P, Patwardhan R, Schenker S, Branch RA: Mephenytoin hydroxylation deficiency: kinetics after repeated doses, 33
- Kurosawa N: *see* Yoshida et al, 681
- Kutt H: *see* Young et al, 540
- Kwong T: *see* Miller et al, 666

## L

- Ladik CF: *see* Kunka et al, 675
- Lalka D: *see* Svensson et al, 660
- Lambe RF: *see* Major et al, 653
- Lant AF: *see* McNabb et al, 328
- Lasagna L: *see* Bakke et al, 559
- Leenen FHH: *see* Chapman et al, 762
- : *see* Reeves et al, 461
- Lerea L: *see* Cubeddu et al, 576
- Levesque C: *see* Thiercelin et al, 510
- Levy RH: *see* Bauer et al, 505
- Lillywhite K: *see* Wing et al, 695
- Linday LA, Drayer DE, Khan MAA, Cicalese C, Reidenberg MM: Pubertal changes in net renal tubular secretion of digoxin, 438
- Linnoila M: *see* Ellinwood et al, 360
- : *see* Martin et al, 322
- Lisansky J: *see* Reyes and Lisansky, 531
- Litwak RS: *see* Reder et al, 454
- Lock CJL: *see* Kean et al, 627
- Longerich LL: *see* Gault et al, 74
- : *see* Gault et al, 750
- Loo JCK: *see* Gault et al, 74



Luderer JR, Patel IH, Durkin J, Schneck DW: Age and ceftriaxone kinetics, 19

# M

MacLeod S: *see* Rajchgot et al, 394

Madhavan SV: *see* Meredith et al, 474

Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF: Isosorbide 5-mononitrate kinetics, 653

Manley MW: *see* Young et al, 540

March L: *see* Arnold et al, 716

Maronde R: *see* Vlachakis et al, 782

Martin LE: *see* Smith et al, 487

Martin PR, Ebert MH, Gordon EK, Linnoila M, Kopin IJ: Effect of clonidine on central and peripheral catecholamine metabolism, 322

Martyn JAJ, Abernethy DR, Greenblatt DJ: Plasma protein binding of drugs after severe burn injury, 535

Mashford ML: *see* Desmond et al, 338

Mauriello PM: *see* Svensson et al, 660

Maxwell BM: *see* Blair et al, 798

McCallum RW: *see* Holloway et al, 203

McClain CJ: *see* Kramer et al, 416

McMahon FG, Ryan JR, Akdamar K, Ertan A: Effect of potassium chloride supplements on upper gastrointestinal mucosa, 852

—: *see* Ryan et al, 90

McNabb ME: *see* Ebert et al, 495

McNabb WR, Noormohamed FH, Brooks BA, Lant AF: Renal actions of piretanide and three other "loop" diuretics, 328

McQuay H: *see* Moore et al, 40

—: *see* Moore et al, 641

Mellstrand T: *see* Hedner et al, 604

Mendelson JH, Ellingboe J, Judson BA, Goldstein A: Plasma testosterone and leuteinizing hormone levels during levo-alpha-acetyl-metadrol maintenance and withdrawal, 545

Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S: Diphenhydramine disposition in chronic liver disease, 474

Meredith PA: *see* Elliott et al, 156

Meyer M: *see* Gyves et al, 83

Middleton E Jr: *see* Svensson et al, 660

Miller KW: *see* Pancorbo et al, 50

Miller M, Cosgriff J, Kwong T, Morken DA: Influence of phenytoin on theophylline clearance, 666

—, Opheim KE, Raisys VA, Motulsky AG: Theophylline metabolism: variation and genetics, 170

Mindich B: *see* Reder et al, 454

Miners JO, Attwood J, Birkett DJ: Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways, 480

—: *see* Wing et al, 695

Miser J: *see* Zimm et al, 826

Möller M: *see* Kampf et al, 214

Molter DW: *see* Ellinwood et al, 360

Moore A, Bullingham R, McQuay H, Allen M, Baldwin D, Cole A: Spinal fluid kinetics of morphine and heroin, 40

—, Sear J, Baldwin D, Allen M, Hunniset A, Bullingham R, McQuay H: Morphine kinetics during and after renal transplantation, 641

Morganroth J: *see* Brazzell et al, 307

Morken DA: *see* Miller et al, 666

Morphett BJ: *see* Desmond et al, 338

Morrison G, Chiang ST, Koepke HH, Walker BR: Effect of renal impairment and hemodialysis on lorazepam kinetics, 646

Morselli PL: *see* Palminteri et al, 141

Motolese M: *see* Corea et al, 776

Motulsky AG: *see* Miller et al, 170

Mullane JF: *see* Arnold et al, 716

Mwaluko G: *see* Campbell et al, 55

Myers JA: *see* Denson et al, 409

—: *see* Denson et al, 702

# N

Nablo L: *see* Kean et al, 627

Nadler PI: *see* Wills et al, 722

Naranjo CA, Sellers EM, Roach CA, Woodley DV, Sanchez-Craig M, Sykora K: Zimeldine-induced variations in alcohol intake by non-depressed heavy drinkers, 374

Nascimento L, Oliveros FH, Cunningham E: Renal handling of sodium and calcium in hypercalciuria, 342

Niederhuber JE: *see* Gyves et al, 83

Nies AS: *see* Hiatt et al, 12

Nioka M: *see* Yoshida et al, 681

Noormohamed FH: *see* McNabb et al, 328

Nyberg G: *see* Hedner et al, 604

# O

Oates JA: *see* FitzGerald and Oates, 633

Oddie C: *see* Jennings et al, 594

Olanoff LS, Walle T, Walle UK, Cowart D, Gaffney TE: Stereoselective clearance and distribution of intravenous propranolol, 755

Oliveros FH: *see* Nascimento et al, 342

Onstad G: *see* Pancorbo et al, 50

Opheim KE: *see* Miller et al, 170

Owada E: *see* Yoshida et al, 681

# P

Pacifici GM, Taddeucci-Brunelli G: Clonazepam serum protein binding during development, 354

Palminteri R, Assael BM, Bianchetti G, Gomeni R, Claris-Appiani A, Edefonti A, Morselli PL: Betaxolol kinetics in hypertensive children with normal and abnormal renal function, 141

- Pancorbo S, Bubrick MP, Chin TWF, Miller KW, Onstad G: Cimetidine dynamics after repeated intravenous injection, 50
- Pantuck CB: *see* Pantuck et al, 161
- Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A: Effect of Brussels sprouts and cabbage on drug conjugation, 161
- Park GD: *see* Radomski et al, 402
- Parsons G: *see* Günsberg et al, 585
- Patel IH: *see* Luderer et al, 19
- Patwardhan R: *see* Küpfer et al, 33
- Pauwels R: *see* Ryrfeldt et al, 525
- Pedrinelli R: *see* Fouad et al, 768
- Pelz K: *see* Keller et al, 208
- Perdomo CA: *see* Arnold et al, 716
- Perlman M: *see* Rajchgot et al, 394
- Perry W, Stamp TCB: Urinary D-glucuric acid excretion during rifampicin/isoniazid and anticonvulsant enzyme induction, 710
- Pitlick W: *see* Theodore et al, 822
- Platia EV, Reid PR: Dose-ranging studies of clofilium, an antiarrhythmic quaternary ammonium, 193
- Ponganis KV: *see* Holley et al, 617
- Poplack DG: *see* Zimm et al, 826
- Porter RJ: *see* Theodore et al, 822
- Prober CG: *see* Rajchgot et al, 394

## Q

- Qu Z-P: *see* Theodore et al, 822
- Quee CK: *see* Radomski et al, 402
- Quiroz AC: *see* Giles et al, 301

## R

- Radomski L, Park GD, Goldberg MJ, Spector R, Johnson GF, Quee CK: Model for theophylline overdose treatment with oral activated charcoal, 402
- Radwanski E: *see* Chung et al, 520
- : *see* Chung et al, 838
- Raisys V: *see* Bauer et al, 505
- : *see* Miller et al, 170
- Rajchgot P, Prober CG, Soldin S, Perlman M, Good F, Harding E, Klein J, MacLeod S: Aminoglycoside-related nephrotoxicity in the premature newborn, 394
- Raymond G: *see* Villeneuve et al, 831
- Rebuck AS: *see* Chapman et al, 762
- Reddy CP, Benes J, Beck B: Intravenous disopyramide: safety and efficacy of a new dosage regimen, 610
- Reder RF, Mindich B, Halperin J, Litwak RS, Kupersmith J: Acute effects of oral labetalol on myocardial conduction after coronary artery bypass grafting, 454

- Reeves RA, Boer WH, DeLeve L, Leenen FHH: Non-selective beta-blockade enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin in normal man, 461
- Reid JL: *see* Elliott et al, 156
- Reid PR: *see* Platia and Reid, 193
- Reidenberg MM: *see* Lindsay et al, 438
- Reilly DK: *see* Rivera-Calimlim and Reilly, 804
- Reitberg DP, Cumbo TJ, Smith IL, Schentag JJ: Effect of protein binding on cefmenoxime steady-state kinetics in critical patients, 64
- Restall R: *see* Jennings et al, 594
- Reyes E, Lisansky J: Effects of tricyclic antidepressants on platelet monoamine oxidase activity, 531
- Rischke J: *see* Kean et al, 627
- Rivera-Calimlim L, Reilly DK: Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance, 804
- Roach CA: *see* Naranjo et al, 374
- Rocheleau F: *see* Villeneuve et al, 831
- Rogers JF: *see* Cubeddu et al, 576
- Romagnoli A, Keats AS: Ceiling respiratory depression by dezocine, 367
- Rooymans HGM: *see* Edelbroek et al, 467
- Ruo TI: *see* Frederiksen et al, 387
- Russell AS: *see* Edelman et al, 382
- Ryan JR, McMahon FG, Akdamar K, Ertan A, Agrawal N: Mucosal irritant potential of potassium-sparing diuretic and of wax-matrix potassium chloride, 90
- : *see* McMahon et al, 852
- Ryrfeldt Å, Edsbäcker S, Pauwels R: Kinetics of the epimeric glucocorticoid budesonide, 525

## S

- Sanchez-Craig M: *see* Naranjo et al, 374
- Sander GE: *see* Giles et al, 301
- Santos D: *see* Denson et al, 702
- Säwe J: *see* Dahlqvist et al, 815
- Schechter PJ: *see* Sjoerdsma and Schechter, 287
- Schenker S: *see* Küpfer et al, 33
- : *see* Meredith et al, 474
- Schentag JJ: *see* Reitberg et al, 64
- : *see* Smith et al, 487
- Schollmeyer P: *see* Keller et al, 208
- Schneck DW, Vary JE: Mechanism by which hydralazine increases propranolol bioavailability, 447
- : *see* Luderer et al, 19
- Schreuder JN: *see* Edelbroek et al, 467
- Sear J: *see* Moore et al, 641
- Sellers EM: *see* Naranjo et al, 374
- Shader RI: *see* Abernethy et al, 188
- : *see* Abernethy et al, 348
- : *see* Abernethy et al, 792
- Shakarjian M: *see* Cubeddu et al, 576



- Shamoian CA: *see* Young et al, 540  
Shanks CA: *see* Walker et al, 686  
Shapiro BJ: *see* Gong et al, 26  
Shea M, Koziol JA, Howell SB: Kinetics of sodium thiosulfate, cisplatin neutralizer, 419  
Sheiner LB: *see* Fuseau and Sheiner, 733  
Shichinohe T: *see* Yoshida et al, 681  
Simmons MS: *see* Gong et al, 26  
Simon P: *see* Thiercelin et al, 510  
Sjoerdsma A, Schechter PJ: Chemotherapeutic implications of polyamine biosynthesis inhibition, 287  
Sjövqvist F: *see* Dahlqvist et al, 815  
Slusher LB, Vesell ES: Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites, 568  
Smith DL: *see* Chapman et al, 762  
Smith IL, Ziemniak JA, Bernhard H, Eshelman FN, Martin LE, Schentag JJ: Ranitidine disposition and systemic availability in hepatic cirrhosis, 487  
—: *see* Reitberg et al, 64  
Snow SL: *see* Ebert et al, 495  
Soldin S: *see* Rajchgot et al, 394  
Somberg JC: *see* Brazzell et al, 307  
Sorbini CA: *see* Corea et al, 776  
Spector R: *see* Radomski et al, 402  
Spiegel HE: *see* Wills et al, 722  
Stamp TCB: *see* Perry and Stamp, 710  
Stanski DR: *see* Holley et al, 617  
Steiness E: Thiazide-induced potassium loss not prevented by beta blockade, 788  
Stern RM: *see* Kunka et al, 675  
Stetson P: *see* Gyves et al, 83  
Svensson CK, Mauriello PM, Barde SH, Middleton E Jr, Lalka D: Effect of carbohydrates on estimated hepatic blood flow, 660  
Sykora K: *see* Naranjo et al, 374  
Symchowicz S: *see* Chung et al, 520  
—: *see* Chung et al, 838

# T

- Taddeucci-Brunelli G: *see* Pacifici and Taddeucci-Brunelli, 354  
Tanner L: *see* Cubeddu et al, 576  
Tantucci C: *see* Corea et al, 776  
Tarazi RC: *see* Fouad et al, 768  
Tashkin DP: *see* Gong et al, 26  
Taylor T: *see* Major et al, 653  
Textor SC: *see* Fouad et al, 768  
Theodore WH, Qu Z-P, Tsay J-Y, Pitlick W, Porter RJ: Phenytoin: pseudosteady-state phenomenon, 822  
Thiercelin JF, Diquet B, Levesque C, Ghesquière F, Simon P, Viars P: Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery, 510

- Thompson G: *see* Denson et al, 409  
—: *see* Denson et al, 702  
Ts'ao C-H: *see* Frederiksen et al, 387  
Tsay J-Y: *see* Theodore et al, 822  
Tsuru M: *see* Kramer et al, 416  
Turner PA: *see* Denson et al, 702

# V

- van Brummelen P: *see* Kleinbloesem et al, 742  
van de Linde JA: *see* Kleinbloesem et al, 742  
Van Loon J: *see* Campbell et al, 55  
Vary JE: *see* Schneck and Vary, 447  
Vasdev SC: *see* Gault et al, 74  
Velasquez M: *see* Vlachakis et al, 782  
Venkataramanan R: *see* Kunka et al, 675  
Verdecchia P: *see* Corea et al, 776  
Vesell ES: Selection of subjects for investigation of host factors affecting drug response: method to identify new pharmacogenetic conditions, 1  
—: *see* Slusher and Vesell, 568  
Viars P: *see* Thiercelin et al, 510  
Villeneuve JP, Rocheleau F, Raymond G: Triamterene kinetics and dynamics in cirrhosis, 831  
Vincent J: *see* Elliott et al, 156  
Vlachakis ND, Barr J, Velasquez M, Alexander N, Maronde R: Acute effect of labetalol on blood pressure in relation to the sympathetic nervous system and plasma renin activity, 782  
Voogd PJ: *see* Kleinbloesem et al, 742

# W

- Walker BR: *see* Morrison et al, 646  
Walker JS, Shanks CA, Brown KF: Altered d-tubocurarine disposition during cardiopulmonary bypass surgery, 686  
Walker S: *see* Gyves et al, 83  
Walle T: *see* Olanoff et al, 755  
Walle UK: *see* Olanoff et al, 755  
Wang YM: *see* Desmond et al, 338  
Wanwimolruk S: *see* Wing et al, 695  
Wardell WM: *see* Bakke et al, 559  
Wattenberg LW: *see* Pantuck et al, 161  
Weinshilboum RM: *see* Campbell et al, 55  
Wilensky A: *see* Bauer et al, 505  
Wills RJ, Dennis S, Spiegel HE, Gibson DM, Nadler PI: Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection, 722  
Wing LMH, Miners JO, Birkett DJ, Foenander T, Lillywhite K, Wanwimolruk S: Lidocaine disposition—sex differences and effects of cimetidine, 695  
Woodley DV: *see* Naranjo et al, 374  
Wroblewski R: *see* Atkinson et al, 431

## Y

- Yoshida A, Fujita M, Kurosawa N, Nioka M, Shichinohe T, Arakawa M, Fukuda R, Owada E, Ito K: Effects of diltiazem on plasma level and urinary excretion of digoxin in healthy subjects, 681
- Young RC, Alexopoulos GS, Shamoian CA, Manley MW, Dhar AK, Kutt H: Plasma 10-hydroxynortriptyline in elderly depressed patients, 540

## Z

- Zampaglione N: *see* Chung et al, 520
- : *see* Chung et al, 838
- Zerbe GO: *see* Hiatt et al, 12
- Ziemniak JA: *see* Smith et al, 487
- Zimm S, Collins JM, Miser J, Chatterji D, Poplack DG: Cytosine arabinoside cerebrospinal fluid kinetics, 826
- Zitman FG: *see* Edelbroek et al, 467

## Subject Index

### A

- Acetaminophen metabolism, determinants of: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways (Miners et al), 480
- nalbuphine, and their combination in postoperative pain (Forbes et al), 843
- Acid, epsilon-aminocaproic, distribution, elimination, and antifibrinolytic effects in normal subjects, kinetics of (Frederiksen et al), 387
- D-glucuric, excretion, urinary, during rifampicin/isoniazid and anticonvulsant enzyme induction (Perry and Stamp), 710
- glycoprotein, alpha-1-, imipramine binding to, in normal subjects and cardiac patients (Freilich and Giardina), 670
- alpha-, and albumin in human serum bupivacaine binding (Denson et al), 409
- valproic, clearance, diurnal variation in (Bauer et al), 505
- Acidosis, lactic, effects of: bupivacaine protein binding in term parturient (Denson et al), 702
- Adrenoceptor, beta, antagonist with partial agonist activity, time-dependent antihypertensive effect of carteolol (Giles et al), 301
- beta-1 and beta-2 stimulation, preferential, non-invasive assessment of chronotropic and inotropic response to (Corea et al), 776
- Age and ceftriaxone kinetics (Luderer et al), 19
- Agonist activity, partial, beta-adrenoceptor with: time-dependent antihypertensive effect of carteolol (Giles et al), 301
- beta-2, inhaled, hemodynamic effects of (Chapman et al), 762
- Albumin, alpha<sub>1</sub>-acid glycoprotein and, in human serum bupivacaine binding (Denson et al), 409
- Alcohol intake, zimelidine-induced variations in, by nondepressed heavy drinkers (Naranjo et al), 374
- Alpha<sub>1</sub>-acid glycoprotein and albumin in human serum bupivacaine binding (Denson et al), 409
- imipramine binding to, in normal subjects and cardiac patients (Freilich and Giardina), 670

- American Society for Clinical Pharmacology and Therapeutics, abstracts of papers, 223
- meeting program, 113
- message from president, 111
- notes of, 731, 856
- Aminoglycoside-related nephrotoxicity in the premature newborn (Rajchgot et al), 394
- Amitriptyline metabolism in relation to antidepressive effect (Edelbroek et al), 467
- Ammonium, antiarrhythmic quaternary, clofilium, dose-ranging studies of (Platia and Reid), 193
- Angiotensin II, epinephrine, and norepinephrine, nonselective beta-blockade enhances pressor responsiveness to, in normal man (Reeves et al), 461
- Antagonist, beta-adrenoceptor, with partial agonist activity: time-dependent antihypertensive effect of carteolol (Giles et al), 301
- Antiarrhythmic effect, cibenzoline plasma concentration and (Brazzell et al), 307
- quaternary ammonium, clofilium, dose-ranging studies of (Platia and Reid), 193
- Anticoagulation, warfarin, effect of influenza vaccine on (Kramer et al), 416
- Antidepressive effect, amitriptyline metabolism in relation to (Edelbroek et al), 467
- Antidepressants, tricyclic, effects of, on platelet monoamine oxidase activity (Reyes and Lisansky), 531
- Antifibrinolytic effects, distribution, and elimination, epsilon-aminocaproic acid, kinetics of, in normal subjects (Frederiksen et al), 387
- Antihypertensive effect, time-dependent, of carteolol—beta-adrenoceptor antagonist with partial agonist activity (Giles et al), 301
- Antipyrine, debrisoquine, and sparteine metabolism, theophylline metabolism in relation to (Dahlqvist et al), 815
- diazepam, and lorazepam, noninteraction with: ranitidine does not impair oxidative or conjugative metabolism (Abernethy et al), 188
- gastrointestinal absorption of, cimetidine-induced reduction in, and rate constants for formation of its metabolites (Slusher and Vesell), 568
- Antithrombin activity of gold sodium thiomalate (Kean et al), 627
- Aptazapine maleate (USAN List No. 247), 557
- Arthritis, low-dose methotrexate kinetics in (Edelman et al), 382

Aspirin, etodolac, and gastrointestinal microbleeding (Arnold et al), 716

Azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function, kinetic interactions between (Kampf et al), 214

## B

Beta-2 agonist, inhaled, hemodynamic effects of (Chapman et al), 762

-1 and beta-2 adrenoceptor stimulation, preferential, noninvasive assessment of chronotropic and inotropic response to (Corea et al), 776

-adrenoceptor antagonist with partial agonist activity—time-dependent antihypertensive effect of carteolol (Giles et al), 301

-blockade, nonselective, enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man (Reeves et al), 461

selective and nonselective, of peripheral circulation (Hiatt et al), 12

-receptor blockade, kinetics and: rectal and intravenous propranolol infusion to steady state (deLeede et al), 148

Betaxolol kinetics in hypertensive children with normal and abnormal renal function (Palminteri et al), 141

Binding, bupivacaine, human serum, alpha<sub>1</sub>-acid glycoprotein and albumin in (Denson et al), 409

imipramine, to alpha<sub>1</sub>-acid glycoprotein in normal subjects and cardiac patients (Freilich and Giardina), 670

plasma protein, of drugs after severe burn injury (Martyn et al), 535

protein, bupivacaine, in term parturient: effects of lactic acidosis (Denson et al), 702

clonazepam serum, during development (Pacifi et al), 354

effect of, on cefmenoxime steady-state kinetics in critical patients (Reitberg et al), 64

Bioavailability, metronidazole kinetics and, in patients undergoing gastrointestinal surgery (Thiercelin et al), 510

propranolol, mechanism by which hydralazine increases (Schneck and Vary), 447

Biotransformation, digoxin (Gault et al), 74

Blockade, beta, nonselective, enhances pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man (Reeves et al), 461

receptor, kinetics and: rectal and intravenous propranolol infusion to steady state (de Leede et al), 148

selective and nonselective, of peripheral circulation (Hiatt et al), 12

Blockade, beta—cont'd

thiazide-induced potassium loss not prevented by (Steiness), 788

Blood cotinine levels as indicators of smoking treatment outcome (Hall et al), 810

flow, hepatic, estimated, effect of carbohydrates on (Svensson et al), 660

pressure, acute effect of labetalol on, in relation to sympathetic nervous system and plasma renin activity (Vlachakis et al), 782

Books received, 223

Breast milk, excretion of propoxyphene and norpropoxyphene in (Kunka et al), 675

Bronchial effects, acute and subacute, of oral cannabinoids (Gong et al), 26

Brussels sprouts and cabbage, effect of, on drug conjugation (Pantuck et al), 161

Budesonide, epimeric glucocorticoid, kinetics of (Ryrfeldt et al), 525

Bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats (Cubeddu et al), 576

Bupivacaine binding, human serum, alpha<sub>1</sub>-acid glycoprotein and albumin in (Denson et al), 409

protein binding in term parturient: effects of lactic acidosis (Denson et al), 702

Burn injury, severe, plasma protein binding of drugs after (Martyn et al), 535

Bypass, cardiopulmonary, cardiac surgery with, effects of, on lidocaine disposition (Holley et al), 617

surgery, altered *d*-tubocurarine disposition during (Walker et al), 686

## C

Cabbage, brussels sprouts and, effect of, on drug conjugation (Pantuck et al), 161

Calcium, sodium and, in hypercalciuria, renal handling of (Nascimento et al), 342

Cannabinoids, oral, acute and subacute bronchial effects of (Gong et al), 26

Carbetimer (USAN List No. 246), 430

Carbohydrates, effect of, on estimated hepatic blood flow (Svensson et al), 660

Cardiac patients, normal subjects and, imipramine binding to alpha<sub>1</sub>-acid glycoprotein in (Freilich and Giardina), 670

surgery with cardiopulmonary bypass, effects of, on lidocaine disposition (Holley et al), 617

Cardiopulmonary bypass, cardiac surgery with, effects of, on lidocaine disposition (Holley et al), 617

surgery, altered *d*-tubocurarine disposition during (Walker et al), 686

- Cardioselectivity, kinetics, hemodynamics, and metabolic effects of xamoterol (Jennings et al), 594
- Cardiovascular actions of clonidine in normal subjects and spontaneously hypertensive rats, bupropion does not antagonize (Cubeddu et al), 576
- Carteolol, beta-adrenoceptor antagonist with partial agonist activity, time-dependent antihypertensive effect of (Giles et al), 301
- Catecholamine metabolism, central and peripheral, effect of clonidine on (Martin et al), 322
- Catechol-*O*-methyltransferase activity(ies), erythrocyte, difference in, between Orientals and Caucasians: difference in levodopa tolerance (Rivera-Calimlim and Reilly), 804
- platelet phenol sulfotransferase and: correlation with methyltransferase metabolism (Campbell et al), 55
- Caucasians, Orientals and, difference in erythrocyte catechol-*O*-methyltransferase activity between: difference in levodopa tolerance (Rivera-Calimlim and Reilly), 804
- Cefmenoxime steady-state kinetics in critical patients, effect of protein binding on (Reitberg et al), 64
- Cefonicid kinetics in subjects with normal and impaired renal function (Blair et al), 798
- Cefoperazone, intraperitoneal and intravenous, kinetics during continuous ambulatory peritoneal dialysis (Keller et al), 308
- Cefotaxime, azlocillin, and cefotaxime metabolites, kinetic interactions between, in normal and impaired renal function (Kampf et al), 214
- Ceftriaxone kinetics, age and (Luderer et al), 19
- Cefuroxime (USAN List No. 246), 429
- Cerebrospinal fluid kinetics, cytosine arabinoside (Zimm et al), 826
- Charcoal, oral activated, model for theophylline overdose treatment with (Radomski et al), 402
- Chemotherapeutic implications of polyamine biosynthesis inhibition (Sjoerdsma and Schechter), 287
- Children, hypertensive, with normal and abnormal renal function, betaxolol kinetics in (Palminteri et al), 141
- Chromatography, gas-liquid, with nitrogen-phosphorous detection, use of: trimipramine kinetics and absolute bioavailability (Abemethy et al), 348
- Chronotropic and inotropic response, noninvasive assessment of, to preferential beta-1 and beta-2 adrenoceptor stimulation (Corea et al), 776
- Cibenzoline plasma concentration and antiarrhythmic effect (Brazzell et al), 307
- Cigarette smokers, plasma nicotine levels of, effect of nicotine chewing gum on (Ebert et al), 495
- smoking, daily intake of nicotine during (Benowitz and Jacob), 499
- Cilastatin sodium (USAN List No. 244), 109
- Cimetidine dynamics after repeated intravenous injection (Pancorbo et al), 50
- effects of, sex differences and—lidocaine disposition (Wing et al), 695
- induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites (Slusher and Vesell), 568
- interaction with imipramine and nortriptyline (Henauer and Hollister), 183
- ranitidine and, decreased oral warfarin clearance after (Desmond et al), 338
- effects of, on pentagastrin-stimulated gastric acid secretion (Holloway et al), 203
- Circulation, peripheral, selective and nonselective  $\beta$ -blockade of (Hiatt et al), 12
- Cirrhosis, hepatic, ranitidine disposition and systemic availability in (Smith et al), 487
- triamterene kinetics and dynamics in (Villeneuve et al), 831
- Cisplatin neutralizer, sodium thiosulfate, kinetics of (Shea et al), 419
- Clearance and distribution, stereoselective, of intravenous propranolol (Olanoff et al), 755
- decreased oral warfarin, after ranitidine and cimetidine (Desmond et al), 338
- theophylline, influence of phenytoin on (Miller et al), 666
- valproic acid, diurnal variation in (Bauer et al), 505
- Clofilium, antiarrhythmic quaternary ammonium, dose-ranging studies of (Platia and Reid), 193
- Clonazepam serum protein binding during development (Pacifci et al), 354
- Clonidine (USAN List No. 244), 109
- cardiovascular actions of, in normal subjects and spontaneously hypertensive rats, bupropion does not antagonize (Cubeddu et al), 576
- effect of, on central and peripheral catecholamine metabolism (Martin et al), 322
- Cooperation, university and pharmaceutical industry: need to plan for future (Atkinson et al), 431
- Concentration, cibenzoline plasma, and antiarrhythmic effect (Brazzell et al), 307
- Conduction, myocardial, after coronary artery bypass grafting, acute effects of oral labetalol on (Reder et al), 454
- Conjugation, drug, effect of brussels sprouts and cabbage on (Pantuck et al), 161

- Contraceptive(s), oral, effects of, on diazepam-induced psychomotor impairment (Ellinwood et al), 360  
steroids, oral, imipramine disposition in users of (Abernethy et al), 792  
Coronary artery bypass grafting, acute effects of oral labetalol on myocardial conduction after (Reder et al), 454  
Cotinine levels, blood, as indicators of smoking treatment outcome (Hall et al), 810  
Critical patients, cefmenoxime steady-state kinetics in, effect of protein binding on (Reitberg et al), 64  
Cytosine arabinoside cerebrospinal fluid kinetics (Zimm et al), 826

*D*

- Dazopride fumarate (USAN List No. 246), 429  
Debrisoquine, antipyrine, and sparteine metabolism, theophylline metabolism in relation to (Dahlqvist et al), 815  
Depressed patients, elderly, plasma 10-hydroxynortriptyline in (Young et al), 540  
Dezocine, ceiling respiratory depression by (Romagnoli and Keats), 367  
Dialysis, continuous ambulatory peritoneal, intraperitoneal and intravenous cefoperazone kinetics during (Keller et al), 208  
Diazepam, antipyrine, and lorazepam, noninteraction with: ranitidine does not impair oxidative or conjugative metabolism (Abernethy et al), 188  
-induced psychomotor impairment, effects of oral contraceptives on (Ellinwood et al), 360  
Dicirenone (USAN List No. 248), 732  
Digoxin biotransformation (Gault et al), 74  
effect, reduction of, during digoxin-quinidine interaction (Das et al), 317  
plasma level and urinary excretion of, effects of diltiazem on, in healthy subjects (Yoshida et al), 681  
pubertal changes in net renal tubular secretion of (Linday et al), 438  
-rifampin interaction (Gault et al), 750  
Dilevalol hydrochloride (USAN List No. 245), 222  
Diltiazem, effects of, on plasma level and urinary excretion of digoxin in healthy subjects (Yoshida et al), 681  
Diphenhydramine disposition in chronic liver disease (Meredith et al), 474  
Disease, liver, chronic, diphenhydramine disposition in (Meredith et al), 474  
Parkinson's, disposition of oral lisuride in (Burns et al), 548  
rheumatoid, patients with, disposition of and clinical response to salicylates (Günsberg et al), 585  
Disopyramide, intravenous: safety and efficacy of new dosage regimen (Reddy et al), 610  
Distribution, elimination, and antifibrinolytic effects, epsilon-aminocaproic acid, kinetics of, in normal subjects (Frederiksen et al), 387  
Diuretic(s), potassium-sparing, and of wax-matrix potassium chloride, mucosal irritant potential of (Ryan et al), 90  
three other "loop," piretanide and, renal actions of (McNabb et al), 328  
Diurnal variation in valproic acid clearance (Bauer et al), 505  
Dose(s), multiple-, halazepam kinetics (Chung et al), 838  
quazepam kinetics (Chung et al), 520  
-ranging studies of clofilium, antiarrhythmic quaternary ammonium (Platia and Reid), 193  
repeated, kinetics after: mephenytoin hydroxylation deficiency (Küper et al), 33  
Drinkers, nondepressed heavy, alcohol intake by, zimetidine-induced variations in (Naranjo et al), 374

*E*

- Elderly depressed patients, plasma 10-hydroxynortriptyline in (Young et al), 540  
Elimination, distribution, and antifibrinolytic effects, epsilon-aminocaproic acid, kinetics of, in normal subjects (Frederiksen et al), 387  
Enalaprilat (USAN List No. 244), 109  
Enisoprost (USAN List No. 244), 109  
Enoxacin (USAN List No. 244), 109  
Enzyme induction, rifampicin/isoniazid and anticonvulsant, urinary D-glucaric acid excretion during (Perry and Stamp), 710  
Epimeric glucocorticoid budesonide, kinetics of (Ryrfeldt et al), 525  
Epinephrine, norepinephrine, and angiotensin II, nonselective beta-blockade enhances pressor responsiveness to, in normal man (Reeves et al), 461  
Epsilon-aminocaproic acid distribution, elimination, and antifibrinolytic effects, kinetics of, in normal subjects (Frederiksen et al), 387  
Erratum to Borgå et al, 473  
Carr, 337  
Erythrocyte catechol-O-methyltransferase activity-(ies), difference in, between Orientals and Caucasians: difference in levodopa tolerance (Rivera-Calimlim and Reilly), 804  
platelet phenol sulfotransferase and: correlation with methyl dopa metabolism (Campbell et al), 55  
Etodolac, aspirin, and gastrointestinal microbleeding (Arnold et al), 716



- Excretion of propoxyphene and norpropoxyphene in breast milk (Kunka et al), 675  
  urinary, of digoxin, plasma level and, effects of diltiazem on, in healthy subjects (Yoshida et al), 681  
Exercise, isometric, rest and, effects during: guanfacine in essential hypertension (Hedner et al), 604

F

- Fezolamine fumarate (USAN List No. 246), 430  
5-Fluorouracil infusion, constant intraperitoneal, through totally implanted system (Gyves et al), 83  
Fluzinamide (USAN List No. 245), 222  
Fostedil (USAN List No. 244), 109

G

- Gas-liquid chromatography with nitrogen-phosphorus detection, use of: trimipramine kinetics and absolute bioavailability (Abernethy et al), 348  
Gastric acid secretion, pentagastrin-stimulated, effects of ranitidine and cimetidine on (Holloway et al), 203  
Gastrointestinal absorption of antipyrine, cimetidine-induced reduction in, and rate constants for formation of its metabolites (Slusher and Vesell), 568  
  microbleeding, etodolac, aspirin, and (Arnold et al), 716  
  mucosa, upper, effect of potassium chloride supplements on (McMahon et al), 852  
  surgery, metronidazole kinetics and bioavailability in patients undergoing (Thiercelin et al), 510  
Genetics, variation and, theophylline metabolism (Miller et al), 170  
D-Glucaric acid excretion, urinary, during rifampicin/isoniazid and anticonvulsant enzyme induction (Perry and Stamp), 710  
Glucocorticoid, epimeric, budesonide, kinetics of (Ryrfeldt et al), 525  
Gold sodium thiomalate, antithrombin activity of (Kean et al), 627  
Grafting, coronary artery bypass, acute effects of oral labetalol on myocardial conduction after (Reder et al), 454  
Guanfacine in essential hypertension: effects during rest and isometric exercise (Hedner et al), 604  
Gum, nicotine chewing, effect of, on plasma nicotine levels of cigarette smokers (Ebert et al), 495

H

- Halazepam kinetics, multiple-dose (Chung et al), 838  
Hemodialysis, renal impairment and, effect of, on lorazepam kinetics (Morrison et al), 646

- Hemodynamic(s), cardioselectivity, kinetics, and metabolic effects of xamoterol (Jennings et al), 594  
  effects, clinical and systemic, of nitrendipine (Fouad et al), 768  
  of an inhaled beta-2 agonist (Chapman et al), 762  
Hepatic blood flow, estimated, effect of carbohydrates on (Svensson et al), 660  
Heroin, morphine and, spinal fluid kinetics of (Moore et al), 40  
Hormone, luteinizing, and testosterone levels, plasma, during levo-alpha-acetylmethadol maintenance and withdrawal (Mendelson et al), 545  
Host factors affecting drug response, selection of subjects for investigation of: method to identify new pharmacogenetic conditions (Vesell), 1  
Hydralazine increases propranolol bioavailability, mechanism by which (Schneck and Vary), 447  
Hydroxylation deficiency, mephenytoin: kinetics after repeated doses (Küper et al), 33  
10-Hydroxynortriptyline, plasma, in elderly depressed patients (Young et al), 540  
Hypercalciuria, sodium and calcium in, renal handling of (Nascimento et al), 342  
Hypertension, essential, guanfacine in: effects during rest and isometric exercise (Hedner et al), 604  
Hypertensive children with normal and abnormal renal function, betaxolol kinetics in (Palminteri et al), 141  
  spontaneously, rats, bupropion does not antagonize cardiovascular actions of clonidine in normal subjects and (Cubeddu et al), 576

I

- Imipramine and nortriptyline, cimetidine interaction with (Henauer and Hollister), 183  
  binding to alpha-1-acid glycoprotein in normal subjects and cardiac patients (Freilich and Giardina), 670  
  disposition in users of oral contraceptive steroids (Abernethy et al), 792  
Indolapril hydrochloride (USAN List No. 247), 558  
Inducers and inhibitors of drug metabolism, effects of, on acetaminophen's metabolic pathways: determinants of acetaminophen metabolism (Miners et al), 480  
Influenza vaccine, effect of, on warfarin anticoagulation (Kramer et al), 416  
Infusion, 5-fluorouracil, constant intraperitoneal, through a totally implanted system (Gyves et al), 83  
  propranolol, rectal and intravenous, to steady state: kinetics and beta-receptor blockade (de Leede et al), 148

- Inhaled beta-2 agonist, hemodynamic effects of (Chapman et al), 762
- Inhibition, polyamine biosynthesis, chemotherapeutic implications of (Sjoerdsma and Schechter, 387
- selective and nonselective, of thromboxane formation (FitzGerald and Oates), 633
- Inhibitors, inducers and, of drug metabolism, effect of, on acetaminophen's metabolic pathways: determinants of acetaminophen metabolism (Miners et al), 480
- Injection, intravenous, intramuscular, and subcutaneous, interferon kinetics and adverse reactions after (Wills et al), 722
- repeated, cimetidine dynamics after (Pancorbo et al), 50
- Injury, severe burn, plasma protein binding of drugs after (Martyn et al), 535
- Inotropic response, chronotropic and, noninvasive assessment of, to preferential beta-1 and beta-2 adrenoceptor stimulation (Corea et al), 776
- Intake, daily, of nicotine during cigarette smoking (Benowitz and Jacob), 499
- Interaction(s), cimetidine, with imipramine and nortriptyline (Henauer and Hollister), 183
- digoxin-quinidine, reduction of digoxin effect during (Das et al), 317
- kinetic, between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function (Kampf et al), 214
- Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection (Wills et al), 722
- Intramuscular, and subcutaneous injection, interferon kinetics and adverse reactions after (Wills et al), 722
- Intraperitoneal and intravenous cefoperazone kinetics during continuous ambulatory peritoneal dialysis (Keller et al), 208
- 5-fluorouracil infusion, constant, through totally implanted system (Gyves et al), 83
- Intravenous disopyramide: safety and efficacy of new dosage regimen (Reddy et al), 610
- infusion, rectal and, of propranolol to steady state: kinetics and beta-receptor blockade (de Leede et al), 148
- injection, repeated, cimetidine dynamics after (Pancorbo et al), 50
- intramuscular, and subcutaneous injection, interferon kinetics and adverse reactions after (Wills et al), 722
- intraperitoneal and, cefoperazone kinetics during continuous ambulatory peritoneal dialysis (Keller et al), 208
- propranolol, stereoselective clearance and distribution of (Olanoff et al), 755
- Iotrol (USAN List No. 426), 430
- Iproplatin (USAN List No. 248), 732
- Isoniazid/rifampicin and anticonvulsant enzyme induction, urinary D-glucuric acid excretion during (Perry and Stamp), 710
- Isosorbide 5-mononitrate kinetics (Major et al), 653
- K*
- Kinetics: *see* specific drug
- L*
- Labetalol, acute effect of, on blood pressure in relation to sympathetic nervous system and plasma renin activity (Vlachakis et al), 782
- oral, acute effects of, on myocardial conduction after coronary artery bypass grafting (Reder et al), 454
- Laurocapram (USAN List No. 245), 221
- Levo-alpha-acetylmethadol maintenance and withdrawal, plasma testosterone and luteinizing hormone levels during (Mendelson et al), 545
- Levodopa tolerance, difference in: difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians (Rivera-Calimlim and Reilly), 804
- Lidocaine disposition, effects of cardiac surgery with cardiopulmonary bypass on (Holley et al), 617
- sex differences and effects of cimetidine (Wing et al), 695
- Lisinopril (USAN List No. 248), 731
- Lisuride, oral, disposition of, in Parkinson's disease (Burns et al), 548
- Liver disease, chronic, diphenhydramine disposition in (Meredith et al), 474
- human, sparteine oxidation by: absence of inhibition by mephenytoin (Jurima et al), 426
- Lofemizole hydrochloride (USAN List No. 245), 221
- "Loop" diuretics, three other, piretanide and, renal action of (McNabb et al), 328
- Lorazepam, antipyrine, diazepam and, noninteraction with: ranitidine does not impair oxidative or conjugative metabolism (Abernethy et al), 188
- kinetics, effect of renal impairment and hemodialysis on (Morrison et al), 646
- Luteinizing hormone, testosterone levels and, plasma, during levo-alpha-acetylmethadol maintenance and withdrawal (Mendelson et al), 545
- M*
- Mephenytoin, absence of inhibition by: sparteine oxidation by human liver (Jurima et al), 426
- hydroxylation deficiency: kinetics after repeated doses (Küpfer et al), 33

Metabolic effects, cardioselectivity, kinetics, hemodynamics and, of xamoterol (Jennings et al), 594

pathways, acetaminophen's, effect of inducers and inhibitors of drug metabolism on: determinants of acetaminophen metabolism (Miners et al), 480

Metabolism, acetaminophen, determinants of: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways (Miners et al), 480

amitriptyline, in relation to antidepressive effect (Edelbroek et al), 467

catecholamine, central and peripheral, effects of clonidine on (Martin et al), 322

methyl dopa, correlation with: platelet phenol sulfotransferase and erythrocyte catechol-*O*-methyltransferase activities (Campbell et al), 55

oxidative or conjugative, ranitidine does not impair: noninteraction with antipyrine, diazepam, and lorazepam (Abernethy et al), 188

theophylline, in relation to antipyrine, debrisoquine, and sparteine metabolism (Dahlqvist et al), 815

variation and genetics (Miller et al), 170

Metabolites, antipyrine, rate constants for formation of, and cimetidine-induced reduction in gastrointestinal absorption of antipyrine (Slusher and Vesell), 568

cefotaxime, azlocillin, and cefotaxime, kinetic interactions between, in normal and impaired renal function (Kampf et al), 214

Methotrexate, low-dose, kinetics in arthritis (Edelman et al), 382

Methyl dopa metabolism, correlation with platelet phenol sulfotransferase and erythrocyte catechol-*O*-methyltransferase activities (Campbell et al), 55

Metronidazole kinetics and bioavailability in patients undergoing gastrointestinal surgery (Thiercelin et al), 510

Microbleeding, gastrointestinal, etodolac, aspirin and (Arnold et al), 716

Mifobate (USAN List No. 248), 731

Milk, breast, excretion of propoxyphene and norpropoxyphene in (Kunka et al), 675

Mioflazine hydrochloride (USAN List No. 245), 221

Modeling, simultaneous, of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model (Fuscau and Sheiner), 733

Monoamine oxidase activity, platelet, effects of tricyclic antidepressants on (Reyes and Lisansky), 531

Morphine and heroin, spinal fluid kinetics of (Moore et al), 40

Morphine—cont'd

kinetics during and after renal transplantation (Moore et al), 641

Mucosa, upper gastrointestinal, effect of potassium chloride supplements on (McMahon et al), 852

Mucosal irritant potential of potassium-sparing diuretic and of wax-matrix potassium chloride (Ryan et al), 90

## N

Naflocort (USAN List No. 247), 557

Nalbuphine, acetaminophen, and their combination in postoperative pain (Forbes et al), 843

oral, in postpartum pain (Kantor and Hopper), 46

Nefazodone hydrochloride (USAN List No. 247), 558

Nephrotoxicity, aminoglycoside-related, in premature newborn (Rajchgot et al), 394

Nervous system, sympathetic, and plasma renin activity, acute effect of labetalol on blood pressure in relation to (Vlachakis et al), 782

Neutralizer, cisplatin, sodium thiosulfate, kinetics of (Shea et al), 419

Newborn, premature, aminoglycoside-related nephrotoxicity in (Rajchgot et al), 394

Nicotine chewing gum, effect of, on plasma nicotine levels of cigarette smokers (Ebert et al), 495

daily intake of, during cigarette smoking (Benowitz and Jacob), 499

Nifedipine: kinetics and dynamics in healthy subjects (Kleinbloesem et al), 742

Nitrendipine, clinical and systemic hemodynamic effects of (Fouad et al), 768

Nitrogen-phosphorus detection, gas-liquid chromatography with, use of: trimipramine kinetics and absolute bioavailability (Abernethy et al), 348

Norepinephrine, angiotensin II, and epinephrine, nonselective beta-blockade enhances pressor responsiveness to, in normal man (Reeves et al), 461

Norfloxacin (USAN List No. 245), 222

Normotensive subjects, trimazosin in (Elliott et al), 156

Norpropoxyphene, propoxyphene and, excretion of, in breast milk (Kunka et al), 675

Nortriptyline, imipramine and, cimetidine interaction with (Henauer and Hollister), 183

Nuclear magnetic resonance, scintigraphy and: their potential applications in pharmacology; New radiopharmaceuticals and spin drugs: their potential implications for scintigraphy and nuclear magnetic resonance. I (Carr), 94; II (Carr), 131

## O

- Oral activated charcoal, model for theophylline overdose treatment with (Radomski et al), 402
- cannabinoids, acute and subacute bronchial effects of (Gong et al), 26
- contraceptive(s), effects of, on diazepam-induced psychomotor impairment (Ellinwood et al), 360
- steroids, imipramine disposition in users of (Abermethyl et al), 792
- labetalol, acute effects of, on myocardial conduction after coronary artery bypass grafting (Reder et al), 454
- lisuride, disposition of, in Parkinson's disease (Burns et al), 548
- nalbuphine in postpartum pain (Kantor and Hopper), 46
- warfarin clearance, decreased, after ranitidine and cimetidine (Desmond et al), 338
- Orientals and Caucasians, difference in erythrocyte catechol-O-methyltransferase activity between: difference in levodopa tolerance (Rivera-Calimlim and Reilly), 804
- Overdose treatment, theophylline, model for, with oral activated charcoal (Radomski et al), 402
- Oxidation, sparteine, by human liver: absence of inhibition by mephentermine (Jurima et al), 426

## P

- Pain, postoperative, nalbuphine, acetaminophen, and their combination in (Forbes et al), 843
- postpartum, oral nalbuphine in (Kantor and Hopper), 46
- Parkinson's disease, disposition of oral lisuride in (Burns et al), 548
- Parturient, term, bupivacaine protein binding in: effects of lactic acidosis (Denson et al), 702
- Paulomycin (USAN List No. 426), 430
- Pentagastrin-stimulated gastric acid secretion, effects of ranitidine and of cimetidine on (Holloway et al), 203
- Pharmaceutical industry cooperation, university and: need to plan for future (Atkinson et al), 431
- Pharmacogenetic conditions, new, method to identify: selection of subjects for investigation of host factors affecting drug response (Vesell), 1
- Phenol sulfotransferase, platelet, and erythrocyte catechol-O-methyltransferase activities: correlation with methyl dopa metabolism (Campbell et al), 55
- Phenytoin, influence of, on theophylline clearance (Miller et al), 666
- pseudosteady-state phenomenon (Theodore et al), 822
- Pinacidil (USAN List No. 246), 429
- Piretanide and three other "loop" diuretics, renal actions of (McNabb et al), 328
- Plasma 10-hydroxynortriptyline in elderly depressed patients (Young et al), 540
- level and urinary excretion of digoxin, effects of diltiazem on, in healthy subjects (Yoshida et al), 681
- protein binding of drugs after severe burn injury (Martyn et al), 535
- renin activity, sympathetic nervous system and, acute effect of labetalol on blood pressure in relation to (Vlachakis et al), 782
- testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal (Mendelson et al), 545
- Platelet monoamine oxidase activity, effects of trycyclic antidepressants on (Reyes and Lisansky), 531
- phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyl dopa metabolism (Campbell et al), 55
- Polyamine biosynthesis inhibition, chemotherapeutic implications of (Sjoerdsma and Schechter), 387
- Potassium chloride supplements, effect of, on upper gastrointestinal mucosa (McMahon et al), 852
- loss, thiazide-induced, not prevented by beta blockade (Steiness), 788
- sparing diuretic and wax-matrix potassium chloride, mucosal irritant potential of (Ryan et al), 90
- Pressor responsiveness to epinephrine, norepinephrine, and angiotensin II in normal man, nonselective beta-blockade enhances (Reeves et al), 461
- Propofol (USAN List No. 248), 732
- Propoxyphene and norpropoxyphene, excretion of, in breast milk (Kunka et al), 675
- Propranolol bioavailability, mechanism by which hydralazine increases (Schneck and Vary), 447
- infusion, rectal and intravenous, to steady state: kinetics and beta-receptor blockade (de Leede et al), 148
- intravenous, stereoselective clearance and distribution of (Olanoff et al), 755
- Protein binding, bupivacaine, in term parturient: effects of lactic acidosis (Denson et al), 702
- clonazepam serum, during development (Pacifi et al), 354
- effect of, on cefmenoxime steady-state kinetics in critical patients (Reitberg et al), 64
- plasma, of drugs after severe burn injury (Martyn et al), 535

- Pseudosteady-state phenomenon: phenytoin (Theodore et al), 822
- Psychomotor impairment, diazepam-induced, effects of oral contraceptives on (Ellinwood et al), 360
- Pubertal changes in net renal tubular secretion of digoxin (Linday et al), 438

Q

- Quazepam kinetics, multiple-dose (Chung et al), 520
- Quinidine-digoxin interaction, reduction of digoxin effect during (Das et al), 317

R

- Radiopharmaceuticals, new, and spin drugs: their potential implications for scintigraphy and nuclear magnetic resonance; Scintigraphy and nuclear magnetic resonance: their potential applications in pharmacology. I (Carr), 94; II (Carr), 131
- Ranitidine and cimetidine, decreased oral warfarin clearance after (Desmond et al), 338
- effects of, on pentagastrin-stimulated gastric acid secretion (Holloway et al), 203
- does not impair oxidative or conjugative metabolism: noninteraction with antipyrine, diazepam, and lorazepam (Abernethy et al), 188
- disposition and systemic availability in hepatic cirrhosis (Smith et al), 487
- Rate constants for formation of its metabolites, cimetidine-induced reduction in gastrointestinal absorption of antipyrine and (Slusher and Vesell), 568
- Rats, spontaneously hypertensive, normal subjects and, bupropion does not antagonize cardiovascular actions of clonidine in (Cubeddu et al), 576
- Rectal and intravenous propranolol infusion to steady state: kinetics and beta-receptor blockade (de Leede et al), 148
- Renal actions of piretanide and three other "loop" diuretics (McNabb et al), 328
- function, normal and abnormal, hypertensive children with, betaxolol kinetics in (Palmini et al), 141
- and impaired, cefonicid kinetics in subjects with (Blair et al), 798
- and impaired, kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in (Kampf et al), 214
- handling of sodium and calcium in hypercalciuria (Nascimento et al), 342
- impairment and hemodialysis, effect of, on lorazepam kinetics (Morrison et al), 646
- transplantation, morphine kinetics during and after (Moore et al), 641

- Renal—cont'd
- tubular secretion, net, of digoxin, pubertal changes in (Linday et al), 438
- Respiratory depression, ceiling, by dezocine (Romagnoli and Keats), 367
- Rest and isometric exercise, effects during: guanfacine in essential hypertension (Hedner et al), 604
- Rheumatoid disease, patients with, disposition of and clinical response to salicylates (Günsberg et al), 585
- Rifampicin-isoniazid and anticonvulsant enzyme induction, urinary D-glucaric acid excretion during (Perry and Stamp), 710
- Rifampin-digoxin interaction (Gault et al), 750

S

- Safety and efficacy of new dosage regimen: intravenous disopyramide (Reddy et al), 610
- issues of: drug discontinuations in United Kingdom and United States, 1964 to 1983 (Bakke et al), 559
- Salicylates, disposition of and clinical response to, in patients with rheumatoid disease (Günsberg et al), 585
- Scintigraphy and nuclear magnetic resonance: their potential applications in pharmacology; New radiopharmaceuticals and spin drugs: their potential implications for scintigraphy and nuclear magnetic resonance. I (Carr), 94; II (Carr), 131
- Secretion, gastric acid, pentagastrin-stimulated, effects of ranitidine and of cimetidine on (Holloway et al), 203
- net renal tubular, of digoxin, pubertal changes in (Linday et al), 438
- Sex differences and effects of cimetidine—lidocaine disposition (Wing et al), 695
- Smokers, cigarette, effect of nicotine chewing gum on plasma nicotine levels of (Ebert et al), 495
- Smoking, cigarette, daily intake of nicotine during (Benowitz and Jacob), 499
- treatment outcome, blood cotinine levels as indicators of (Hall et al), 810
- Sodium and calcium, renal handling of, in hypercalciuria (Nascimento et al), 342
- thiosulfate, a cisplatin neutralizer, kinetics of (Shea et al), 419
- Somantadine hydrochloride (USAN List No. 245), 222
- Sparteine, antipyrine, and debrisoquine metabolism, theophylline metabolism in relation to (Dahlqvist et al), 815
- oxidation by human liver: absence of inhibition by mephenytoin (Jurima et al), 426



- Spin drugs, new radiopharmaceuticals and: their potential implications for scintigraphy and nuclear magnetic resonance; Scintigraphy and nuclear magnetic resonance: their potential applications in pharmacology. I (Carr), 94; II (Carr), 131
- Spinal fluid kinetics of morphine and heroin (Moore et al), 40
- Steady-state, pseudo-, phenomenon: phenytoin (Theodore et al), 822
- Steroids, oral contraceptive, imipramine disposition in users of (Abernethy et al), 792
- Subcutaneous, intramuscular, and intravenous injection, interferon kinetics and adverse reactions after (Wills et al), 722
- Sulbactam benzathine (USAN List No. 248), 732
- Supplements, potassium chloride, effect of, on upper gastrointestinal mucosa (McMahon et al), 852
- Surgery, cardiac, with cardiopulmonary bypass, effects of, on lidocaine disposition (Holley et al), 617
- cardiopulmonary bypass, altered *d*-tubocurarine disposition during (Walker et al), 686
- gastrointestinal, metronidazole kinetics and bioavailability in patients undergoing (Thiercelin et al), 510
- Systemic availability, ranitidine disposition and, in hepatic cirrhosis (Smith et al), 487

*T*

- Testosterone and luteinizing hormone levels, plasma, during levo-alpha-acetylmethadol maintenance and withdrawal (Mendelson et al), 545
- Theophylline clearance, influence of phenytoin on (Miller et al), 666
- metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism (Dahlqvist et al), 815
- variation and genetics (Miller et al), 170
- overdose treatment with oral activated charcoal, model for (Radomski et al), 402
- Thiazide-induced potassium loss not prevented by beta blockade (Steiness), 788
- Thromboxane formation, selective and nonselective inhibition of (FitzGerald and Oates), 633
- Timobesone acetate (USAN List No. 248), 731
- Transplantation, renal, morphine kinetics during and after (Moore et al), 641

- Triamterene kinetics and dynamics in cirrhosis (Vileneuve et al), 831
- Trimazosin in normotensive subjects (Elliott et al), 156
- Trimethoprim sulfate (USAN List No. 244), 109
- Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection (Abernethy et al), 348
- d*-Tubocurarine disposition, altered, during cardiopulmonary bypass surgery (Walker et al), 686

*U*

- United Kingdom and United States, drug discontinuations in, 1964 to 1983: issues of safety (Bakke et al), 559
- United States, United Kingdom and, drug discontinuations in, 1964 to 1983: issues of safety (Bakke et al), 559
- University and pharmaceutical industry cooperation: need to plan for future (Atkinson et al), 431

*V*

- Vaccine, influenza, effect of, on warfarin anticoagulation (Kramer et al), 416
- Valproic acid clearance, diurnal variation in (Bauer et al), 505
- Variation and genetics, theophylline metabolism (Miller et al), 170
- Vecuronium bromide (USAN List No. 247), 557

*W*

- Warfarin anticoagulation, effect of influenza vaccine on (Kramer et al), 416
- clearance, decreased oral, after ranitidine and cimetidine (Desmond et al), 338
- Wax-matrix potassium chloride, potassium-sparing diuretic and, mucosal irritant potential of (Ryan et al), 90

*X*

- Xamoterol, cardioselectivity, kinetics, hemodynamics, and metabolic effects of (Jennings et al), 594

*Z*

- Zimelidine-induced variations in alcohol intake by nondepressed heavy drinkers (Naranjo et al), 374



